About MetLife (NYSE:MET)
MetLife, Inc., through its subsidiaries, engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, tort settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, the company offers automobile, homeowners', and personal excess liability, as well as small business owners' property, liability, and business interruption insurance products. Further, it provides fixed annuities and pension products; medical and credit insurance products; variable, universal, term, endowment, and whole life insurance products; variable, and fixed and indexed-linked annuities; and protection against costs of long-term health care services. The company serves individuals, corporations and their employees, and other institutions through independent agents, property and casualty specialists, sales forces, sales teams and relationship managers, and other organizations, as well as through career agency, bancassurance, direct marketing, brokerage, and other third-party distribution and e-commerce channels. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
Industry, Sector and Symbol
Sub-IndustryLife & Health Insurance
Trailing P/E Ratio13.8475479400233
Forward P/E Ratio9.58
Sales & Book Value
Annual Sales$62.09 billion
Price / Sales0.79
Cash Flow$4.49 per share
Price / Cash10.52
Book Value$55.94 per share
Price / Book0.84
Net Income$4.01 billion
Return on Equity8.59%
Return on Assets0.66%
MetLife (NYSE:MET) Frequently Asked Questions
What is MetLife's stock symbol?
MetLife trades on the New York Stock Exchange (NYSE) under the ticker symbol "MET."
How often does MetLife pay dividends? What is the dividend yield for MetLife?
MetLife declared a quarterly dividend on Friday, January 5th. Stockholders of record on Monday, February 5th will be given a dividend of $0.40 per share on Tuesday, March 13th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date is Friday, February 2nd. View MetLife's Dividend History.
How were MetLife's earnings last quarter?
MetLife (NYSE:MET) posted its quarterly earnings results on Tuesday, February, 13th. The financial services provider reported $0.64 EPS for the quarter, missing analysts' consensus estimates of $1.05 by $0.41. The financial services provider earned $15.79 billion during the quarter, compared to analyst estimates of $15.89 billion. MetLife had a net margin of 5.69% and a return on equity of 8.59%. During the same quarter last year, the business posted $1.28 EPS. View MetLife's Earnings History.
When will MetLife make its next earnings announcement?
What guidance has MetLife issued on next quarter's earnings?
MetLife updated its fourth quarter earnings guidance on Monday, January, 29th. The company provided earnings per share guidance of $1.07-1.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.07.
Where is MetLife's stock going? Where will MetLife's stock price be in 2018?
15 equities research analysts have issued 12-month target prices for MetLife's stock. Their forecasts range from $51.00 to $78.00. On average, they anticipate MetLife's stock price to reach $58.67 in the next twelve months. View Analyst Ratings for MetLife.
What are Wall Street analysts saying about MetLife stock?
Here are some recent quotes from research analysts about MetLife stock:
- 1. According to Zacks Investment Research, "MetLife’s shares underperformed its industry in a year's time. The company kept a reserve charge of $331 million in its Retirement and Income Solutions (RIS) Segment, which reflects weak internal control. Its investment in efficiency programs is expected to weigh on margins before reaping benefits. Also, exposure to catastrophe induces earnings volatility. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 1.2% downward over the last 60 days. This reflects analysts' pessimism towards the stock. Nevertheless, MetLife's efforts to streamline its business (for the past many years), only to focus on core business, are really impressive. Its strong international operations and disciplined capital management should drive long-term growth." (3/20/2018)
- 2. Wells Fargo analysts commented, "We hosted investor meetings with MetLife today (March 15) at the company’s NYC headquarters. From MET were Steven Kandarian, President, Chairman & CEO; John Hele, EVP & CFO; and John Hall, SVP & Head of IR. Investors were focused on MET’s material weaknesses (MW), unit cost initiative (UCI), long term care reserves, Brighthouse exchange offer, and reinsurance opportunities with MetLife Holdings. To us, the investment case for MET remains unchanged – faster growth in less capital intensive and less volatile businesses should lower the company’s cost of equity, which in turn should allow MetLife to achieve a higher ROE spread as well as a higher valuation multiple. We reiterate our Outperform rating on MET, which is also our top pick." (3/16/2018)
Are investors shorting MetLife?
MetLife saw a increase in short interest in February. As of February 28th, there was short interest totalling 12,608,208 shares, an increase of 25.1% from the February 15th total of 10,079,728 shares. Based on an average daily volume of 6,147,465 shares, the short-interest ratio is presently 2.1 days. Approximately 1.3% of the shares of the company are short sold.
Who are some of MetLife's key competitors?
Some companies that are related to MetLife include China Life Insurance (LFC), Prudential Public (PUK), AXA (AXAHY), Chubb (CB), Zurich Insurance Group (ZURVY), American International Group (AIG), Prudential Financial (PRU), Marsh & McLennan Companies (MMC), CIGNA (CI), Travelers Companies (TRV), Muenchener Rckvrrgs Gsllcht Mhn (MURGY), Manulife Financial (MFC), Swiss Re (SSREY), Progressive (PGR), Aon plc Class A (AON), AFLAC (AFL), Tokio Marine (TKOMY) and Allstate (ALL).
Who are MetLife's key executives?
MetLife's management team includes the folowing people:
- Mr. Steven Albert Kandarian, Chairman, Pres & CEO (Age 65)
- Mr. John Carroll Ramsey Hele, Exec. VP & CFO (Age 60)
- Mr. Steven Jeffery Goulart, Chief Investment Officer & Exec. VP (Age 59)
- Mr. Martin J. Lippert, Head of Global Technology & Operations and Exec. VP (Age 58)
- Ms. Kirstie Traas, Head of Operations
Has MetLife been receiving favorable news coverage?
Media stories about MET stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MetLife earned a news sentiment score of 0.20 on Accern's scale. They also gave press coverage about the financial services provider an impact score of 44.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are MetLife's major shareholders?
MetLife's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
BOARD OF DIRECTORS OF METLIFE INC
(14.90%), BlackRock Inc. (6.96%), Franklin Resources Inc. (2.44%), Bank of New York Mellon Corp (1.16%), Geode Capital Management LLC (1.00%) and Clearbridge Investments LLC (0.95%). Company insiders that own MetLife stock include Christopher G Townsend, Frans Hijkoop, James M Kilts, Maria R Morris and Peter M Carlson. View Institutional Ownership Trends for MetLife.
Which major investors are selling MetLife stock?
MET stock was sold by a variety of institutional investors in the last quarter, including NWQ Investment Management Company LLC, OppenheimerFunds Inc., Clearbridge LLC, Quantitative Investment Management LLC, Acadian Asset Management LLC, The Manufacturers Life Insurance Company , Metropolitan Life Insurance Co. NY and UBS Asset Management Americas Inc.. View Insider Buying and Selling for MetLife.
Which major investors are buying MetLife stock?
MET stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Alps Advisors Inc., TCW Group Inc., American Century Companies Inc., Jennison Associates LLC, Nuance Investments LLC, Amundi Pioneer Asset Management Inc. and RiverPoint Capital Management LLC. View Insider Buying and Selling for MetLife.
How do I buy shares of MetLife?
Shares of MET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MetLife's stock price today?
One share of MET stock can currently be purchased for approximately $47.22.
How big of a company is MetLife?
MetLife has a market capitalization of $48.82 billion and generates $62.09 billion in revenue each year. The financial services provider earns $4.01 billion in net income (profit) each year or $3.41 on an earnings per share basis. MetLife employs 49,000 workers across the globe.
How can I contact MetLife?
MetLife's mailing address is 200 Park Avenue, New York NY, 10166. The financial services provider can be reached via phone at 212-578-9500.
MarketBeat Community Rating for MetLife (MET)MarketBeat's community ratings are surveys of what our community members think about MetLife and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
MetLife (NYSE:MET) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Buy||Buy|
|Consensus Rating Score: ||2.40||2.38||2.50||2.54|
|Ratings Breakdown: ||1 Sell Rating(s)|
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$58.67||$58.60||$59.37||$58.89|
|Price Target Upside: ||24.24% upside||29.65% upside||13.11% upside||22.82% upside|
MetLife (NYSE:MET) Consensus Price Target History
MetLife (NYSE:MET) Analyst Ratings History
(Data available from 3/21/2016 forward)